


ACT Accelerator: Investment Case & Plan

moving from start-up to scale-up

1st meeting of the ACT-A Facilitation Council
10 September 2020

COVID-19 impact | The pandemic endangers all populations and is undermining all of the Sustainable Development Goals




1. Worldwide disruption of healthcare system due to Covid-19, WHO; 2. World bank; 3. Market intelligence ; 4. Effect of covid-19 only, UN

Health impact | The pandemic is still progressing & current public health measures are challenging to maintain overtime


The stringency of NPIs¹ is declining everywhere

Stringency index for COVID-19 government response – as of 31 August, Oxford University



Confirmed cases continue to increase


Cumulative number of cases – as of 29 August 2020, WHO Dashboard




¹. e.g. Social distancing, lockdowns, mandatory masks, etc.

ACT-A is a bold structure, driving **unprecedented collaboration**

Deep engagement
of Co-conveners &
Leads, integrated
workplans &
budgets, working
with industry, civil
society, countries
and the entire
development
system



ACT-A's goal: accelerated global access to tools that will end the acute phase of the pandemic



ACT-A's integrated portfolio, global reach and targets are specifically designed to achieve this goal

	Access & Allocation	Ensure equitable allocation of scarce tools to address severe disease globally			
	Vaccines		Therapeutics		Diagnostics
Accelerate development of safe and efficacious new vaccines		Identify new, more effective treatments		Rapid identification of game-changing new diagnostics	
					
Establish the broadest portfolio of products to mitigate risk		Catalyse manufacturing, procurement and delivery of successful candidates		Bring affordable, high-quality rapid diagnostic tests to market at scale	
					
2 billion doses by the end of 2021		245 million courses by mid-2021		500 million tests by mid-2021	
	Health Systems	Enable effective deployment of tools and safe delivery of health services Supply PPE & Oxygen to those who need it			

ACT-A has an **impressive track record** in just 4 months

Access & Allocation • Global Allocation Framework finalised • Allocation mechanism for COVAX Vaccines drafted		
Vaccines • 200+ candidates being followed • 10 vaccine candidates already in portfolio • Broadest portfolio across geography & tech platforms • COVAX Vaccines Facility engaging with 170 countries	Therapeutics • 1,700+ trials followed, 200+ readouts & 25-30 priorities under monitoring • 15-country trials funded focusing on LMICS • First life-saving therapy for severe disease in roll out to LMICs (Dexamethasone)	Diagnostics • 80+ diagnostics followed • 50+ tests under evaluation • Potentially game-changing rapid test identified • 15+ tests with WHO EUL • 17+ million tests procured
Health Systems • 100+ countries surveyed to identify bottlenecks and capacity gaps • Systems requirements for tool delivery mapped in 4 of 6 regions		



ACT-A needs 2 major step changes in this crucial period

AS OF SEPT 7

Step change in financing to scale up for impact, \$ B rounded



New level of coordination for roll out of scarce vaccines Vaccine doses secured¹, M doses by 2021



¹Based on publicly disclosed agreements

² Cumulative numbers


³ European Commission Inclusive Vaccines Alliance

ACT-A Investment Case

Economic impact | Unprecedented domestic economic stimulus has helped hedge the crisis but only in some sectors & countries


\$US 10 trillion in stimulus unlocked by G20 countries to support businesses & economies

Size of stimulus package – in \$B




Economic support is already showing mixed outlook

Financial indices – 100=1 Jan-20, as of 31 August 2020




EU unemployment rate – in % population¹



¹ Source: OECD Data


Sectors that depend heavily on international trade & mobility will not recover with existing government stimulus



¹ pre-COVID GDP at end of 2021 expected to be \$US 152 trillion worldwide. In April, forecasts post-COVID predicted \$US 138 trillion. The loss for G20 economies would be ~\$US 10 - 13 trillion, IMF, World Bank; ² 2020 Travel & Tourism drop by \$US 3.7 trillion, WTTC; ³ International trade is facing contraction that could reach -32%; IMF, WTO, BCG analysis; ⁴. \$US 3 trillion excluding China. Source: World Bank, WTO, BCG analysis.

Rapidly reducing severe COVID-19 disease in LIC/LMICs would save lives and fully restore international mobility & trade and long term growth

Equitable access to COVID-19 tools will allow LIC/LMIC domestic economies to recover...





...restoring international mobility & trade and delivering short term value and long term growth to HICs.¹

■ Significant investments ■ Limited investments

¹ Emerging markets are contributing to 74% of 2020 GDP growth and 30% of international trade; source: WTO, IMF

The **\$US 35 B** needed to fully fund ACT-A would be paid back in **36 hours**, once international mobility & trade is restored



1. Additional critical funding required by end of 2020 to meet ACT-A targets (excl. proportion already funded); 2. As of 7 September 2020;
3. Assuming 25% of total ask in 2020

ACT-A is the **most effective integrated investment to address COVID-19 globally**

Comprehensive public health tool box

ACT-A is the only mechanism with Vaccines, Therapeutics, Diagnostics, PPE and O2, the full spectrum of products needed to beat the pandemic

Reduces R&D risks

ACT-A has a broad and diverse R&D portfolio


Mitigates operational risks

ACT-A co-conveners are experts in implementing public health measures globally

Unique global reach

ACT-A, by design, is the only mechanism that looks after all people at the same time, everywhere

ACT-A's **critical path** uses **accelerated & parallel workstreams** to rapidly achieve its goal



ACT-A Immediate Priorities (Sep-Dec 2020)

Immediate **product priorities** from Sept – Dec 2020

	 R&D	 Manufacturing	 Procurement	 Delivery
 Vaccines	Add 1-5 candidates to portfolio based on imminent readouts	Negotiate new deals with manufacturers based on imminent Phase II/II results		Step up country preparedness efforts to deploy as soon as possible
 Therapeutics	Evaluate new monoclonal antibodies and antivirals	Select molecules for 1st wave of manufacturing capacity reservations	Launch 3-5 further market interventions for repurposed medicines	Scale up Dexamethasone
 Diagnostics	Accelerate evaluation of novel diagnostics		Roll out 10s of millions of antibody-detecting RDTs	Pre-empt deployment needs for antibody-detecting RDTs

Immediate **cross-cutting priorities** from Sept – Dec 2020



Access & Allocation

- **Operationalise** Allocation Mechanism for **Vaccines**
 - **Finalise** the Allocation Mechanism for **Therapeutics**
-



Health Systems

- Launch **10-15 country pilots** to test and refine overall approach
- Map and **match private sector capacity** to identified **public needs**

The ACT Accelerator is the proven, up-and-running, COVID-19 exit strategy for the world that is already delivering returns.

It is the only mechanism explicitly designed to achieve:

- a simultaneous end to the pandemic everywhere
- with a concomitant return to health, and
- a faster and more sustained return to global mobility, trade & economic activity

ACT-A now needs a step change in support to massively scale up for impact.